Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retatrutide in obesity/overweight with knee osteoarthritis
NCT05931367Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2023
- Primary completion
- Nov 2025
- Modality
- Peptides, Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of retatrutide in obesity, sponsored by Eli Lilly and Company. Started Aug 2023; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05931367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05931367.